{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:36:53Z","timestamp":1775281013907,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Arachidonic acid (AA) is metabolized to diverse bioactive lipid mediators. Whereas the 5-lipoxygenase-activating protein (FLAP) facilitates AA conversion by 5-lipoxygenase (5-LOX) to pro-inflammatory leukotrienes (LTs), the soluble epoxide hydrolase (sEH) degrades anti-inflammatory epoxyeicosatrienoic acids (EETs). Accordingly, dual FLAP\/sEH inhibition might be advantageous drugs for intervention of inflammation. We present the <jats:italic>in vivo<\/jats:italic> pharmacological profile and efficiency of <jats:italic>N<\/jats:italic>-[4-(benzothiazol-2-ylmethoxy)-2-methylphenyl]-<jats:italic>N<\/jats:italic>\u2032-(3,4-dichlorophenyl)urea (diflapolin) that dually targets FLAP and sEH. Diflapolin inhibited 5-LOX product formation in intact human monocytes and neutrophils with IC<jats:sub>50<\/jats:sub>\u2009=\u200930 and 170\u2009nM, respectively, and suppressed the activity of isolated sEH (IC<jats:sub>50<\/jats:sub>\u2009=\u200920\u2009nM). Characteristic for FLAP inhibitors, diflapolin (I) failed to inhibit isolated 5-LOX, (II) blocked 5-LOX product formation in HEK cells only when 5-LOX\/FLAP was co-expressed, (III) lost potency in intact cells when exogenous AA was supplied, and (IV) prevented 5-LOX\/FLAP complex assembly in leukocytes. Diflapolin showed target specificity, as other enzymes related to AA metabolism (i.e., COX1\/2, 12\/15-LOX, LTA<jats:sub>4<\/jats:sub>H, LTC<jats:sub>4<\/jats:sub>S, mPGES<jats:sub>1<\/jats:sub>, and cPLA<jats:sub>2<\/jats:sub>) were not inhibited. In the zymosan-induced mouse peritonitis model, diflapolin impaired vascular permeability, inhibited cysteinyl-LTs and LTB<jats:sub>4<\/jats:sub> formation, and suppressed neutrophil infiltration. Diflapolin is a highly active dual FLAP\/sEH inhibitor <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> with target specificity to treat inflammation-related diseases.<\/jats:p>","DOI":"10.1038\/s41598-017-09795-w","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T15:26:52Z","timestamp":1503070012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase"],"prefix":"10.1038","volume":"7","author":[{"given":"Ulrike","family":"Garscha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Romp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Temml","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9933-8938","authenticated-orcid":false,"given":"Daniela","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Gerstmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Liening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Atze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Weinigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Rummler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard K.","family":"Scriba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Sautebin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Werz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"9795_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molmed.2008.08.005","volume":"14","author":"H Harizi","year":"2008","unstructured":"Harizi, H., Corcuff, J. B. & Gualde, N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med \n                           14, 461\u2013469, doi:10.1016\/j.molmed.2008.08.005 (2008).","journal-title":"Trends Mol Med"},{"key":"9795_CR2","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1021\/cr200246d","volume":"111","author":"JZ Haeggstrom","year":"2011","unstructured":"Haeggstrom, J. Z. & Funk, C. D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. \n                           111, 5866\u20135898, doi:10.1021\/cr200246d (2011).","journal-title":"Chem. Rev."},{"key":"9795_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/0006-291X(81)91597-7","volume":"101","author":"J Capdevila","year":"1981","unstructured":"Capdevila, J. et al. The oxidative metabolism of arachidonic acid by purified cytochromes P-450. Biochem. Biophys. Res. Commun. \n                           101, 1357\u20131363 (1981).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"9795_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","volume":"43","author":"AA Spector","year":"2004","unstructured":"Spector, A. A., Fang, X., Snyder, G. D. & Weintraub, N. L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. \n                           43, 55\u201390 (2004).","journal-title":"Prog. Lipid Res."},{"key":"9795_CR5","doi-asserted-by":"publisher","first-page":"81s","DOI":"10.18433\/J3T886","volume":"11","author":"P Rao","year":"2008","unstructured":"Rao, P. & Knaus, E. E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. \n                           11, 81s\u2013110s (2008).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"9795_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bcpt.12114","volume":"114","author":"D Steinhilber","year":"2014","unstructured":"Steinhilber, D. & Hofmann, B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin. Pharmacol. Toxicol. \n                           114, 70\u201377, doi:10.1111\/bcpt.12114 (2014).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"9795_CR7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1039\/c2mb05503a","volume":"8","author":"C He","year":"2012","unstructured":"He, C. et al. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. Mol. Biosyst. \n                           8, 1585\u20131594, doi:10.1039\/c2mb05503a (2012).","journal-title":"Mol. Biosyst."},{"key":"9795_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00063198-200401000-00009","volume":"10","author":"A Szczeklik","year":"2004","unstructured":"Szczeklik, A., Sanak, M., Nizankowska-Mogilnicka, E. & Kielbasa, B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr. Opin. Pulm. Med. \n                           10, 51\u201356 (2004).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"9795_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1006\/phrs.2000.0784","volume":"43","author":"F Celotti","year":"2001","unstructured":"Celotti, F. & Laufer, S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. \n                           43, 429\u2013436, doi:10.1006\/phrs.2000.0784 (2001).","journal-title":"Pharmacol. Res."},{"key":"9795_CR10","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy, R. & Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. \n                           48, 6523\u20136543, doi:10.1021\/jm058225d (2005).","journal-title":"J. Med. Chem."},{"key":"9795_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bcpt.12134","volume":"114","author":"K Meirer","year":"2014","unstructured":"Meirer, K., Steinhilber, D. & Proschak, E. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin. Pharmacol. Toxicol. \n                           114, 83\u201391, doi:10.1111\/bcpt.12134 (2014).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"9795_CR12","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1021\/jm2001376","volume":"54","author":"SH Hwang","year":"2011","unstructured":"Hwang, S. H. et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J. Med. Chem. \n                           54, 3037\u20133050, doi:10.1021\/jm2001376 (2011).","journal-title":"J. Med. Chem."},{"key":"9795_CR13","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1021\/jm301617j","volume":"56","author":"K Meirer","year":"2013","unstructured":"Meirer, K. et al. Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase. J. Med. Chem. \n                           56, 1777\u20131781, doi:10.1021\/jm301617j (2013).","journal-title":"J. Med. Chem."},{"key":"9795_CR14","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","volume":"19","author":"A Koeberle","year":"2014","unstructured":"Koeberle, A. & Werz, O. Multi-target approach for natural products in inflammation. Drug Discov. Today \n                           19, 1871\u20131882, doi:10.1016\/j.drudis.2014.08.006 (2014).","journal-title":"Drug Discov. Today"},{"key":"9795_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep42751","volume":"7","author":"V Temml","year":"2017","unstructured":"Temml, V. et al. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening. Sci. Rep. \n                           7, 42751, doi:10.1038\/srep42751 (2017).","journal-title":"Sci. Rep."},{"key":"9795_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/343282a0","volume":"343","author":"RA Dixon","year":"1990","unstructured":"Dixon, R. A. et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature \n                           343, 282\u2013284, doi:10.1038\/343282a0 (1990).","journal-title":"Nature"},{"key":"9795_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tips.2007.11.006","volume":"29","author":"JF Evans","year":"2008","unstructured":"Evans, J. F., Ferguson, A. D., Mosley, R. T. & Hutchinson, J. H. What\u2019s all the FLAP about? 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. \n                           29, 72\u201378, doi:10.1016\/j.tips.2007.11.006 (2008).","journal-title":"Trends Pharmacol. Sci."},{"key":"9795_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1139\/y89-073","volume":"67","author":"J Gillard","year":"1989","unstructured":"Gillard, J. et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. \n                           67, 456\u2013464 (1989).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"9795_CR19","first-page":"245","volume":"6","author":"R Muller-Peddinghaus","year":"1993","unstructured":"Muller-Peddinghaus, R. et al. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J. Lipid Mediat. \n                           6, 245\u2013248 (1993).","journal-title":"J. Lipid Mediat."},{"key":"9795_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","volume":"53","author":"C Morisseau","year":"2013","unstructured":"Morisseau, C. & Hammock, B. D. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. \n                           53, 37\u201358, doi:10.1146\/annurev-pharmtox-011112-140244 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"9795_CR21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.bcp.2009.10.025","volume":"79","author":"JY Liu","year":"2010","unstructured":"Liu, J. Y. et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem. Pharmacol. \n                           79, 880\u2013887, doi:10.1016\/j.bcp.2009.10.025 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"9795_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011979","volume":"5","author":"O Jung","year":"2010","unstructured":"Jung, O. et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One \n                           5, e11979, doi:10.1371\/journal.pone.0011979 (2010).","journal-title":"PLoS One"},{"key":"9795_CR23","doi-asserted-by":"publisher","unstructured":"Werz, O., Gerstmeier, J. & Garscha, U. Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents. Expert Opin. Ther. Pat. 1\u201314, doi:10.1080\/13543776.2017.1276568 (2017).","DOI":"10.1080\/13543776.2017.1276568"},{"key":"9795_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1476-5381.1990.tb12044.x","volume":"100","author":"L Menard","year":"1990","unstructured":"Menard, L., Pilote, S., Naccache, P. H., Laviolette, M. & Borgeat, P. Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br. J. Pharmacol. \n                           100, 15\u201320 (1990).","journal-title":"Br. J. Pharmacol."},{"key":"9795_CR25","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/bph.12592","volume":"171","author":"AM Schaible","year":"2014","unstructured":"Schaible, A. M. et al. Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase. Br. J. Pharmacol. \n                           171, 2399\u20132412, doi:10.1111\/bph.12592 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"9795_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0014-5793(93)80528-3","volume":"318","author":"JA Mancini","year":"1993","unstructured":"Mancini, J. A. et al. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. \n                           318, 277\u2013281 (1993).","journal-title":"FEBS Lett."},{"key":"9795_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bcp.2016.08.023","volume":"119","author":"U Garscha","year":"2016","unstructured":"Garscha, U. et al. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase\/5-lipoxygenase-activating protein (FLAP) complex assembly. Biochem. Pharmacol. \n                           119, 17\u201326, doi:10.1016\/j.bcp.2016.08.023 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"9795_CR28","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1111\/bph.12625","volume":"171","author":"C Pergola","year":"2014","unstructured":"Pergola, C. et al. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). Br. J.Pharmacol. \n                           171, 3051\u20133064, doi:10.1111\/bph.12625 (2014).","journal-title":"Br. J.Pharmacol."},{"key":"9795_CR29","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.bbagen.2014.05.016","volume":"1840","author":"J Gerstmeier","year":"2014","unstructured":"Gerstmeier, J., Weinigel, C., Barz, D., Werz, O. & Garscha, U. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis. Biochim. Biophys. Acta \n                           1840, 2961\u20132969, doi:10.1016\/j.bbagen.2014.05.016 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"9795_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.bbrc.2012.02.108","volume":"419","author":"C Morisseau","year":"2012","unstructured":"Morisseau, C. et al. Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochem. Biophys. Res. Commun. \n                           419, 796\u2013800, doi:10.1016\/j.bbrc.2012.02.108 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"9795_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0006-2952(02)00952-8","volume":"63","author":"C Morisseau","year":"2002","unstructured":"Morisseau, C. et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. \n                           63, 1599\u20131608 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"9795_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1124\/jpet.300.2.577","volume":"300","author":"LJ Askonas","year":"2002","unstructured":"Askonas, L. J. et al. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J. Pharmacol. Exp. Ther. \n                           300, 577\u2013582 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9795_CR33","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-5","volume":"161","author":"PJ Jakobsson","year":"2000","unstructured":"Jakobsson, P. J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A. & Persson, B. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am. J. Respir. Crit. Care Med. \n                           161, S20\u201324, doi:10.1164\/ajrccm.161.supplement_1.ltta-5 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"9795_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.sbi.2008.04.005","volume":"18","author":"D Martinez Molina","year":"2008","unstructured":"Martinez Molina, D., Eshaghi, S. & Nordlund, P. Catalysis within the lipid bilayer-structure and mechanism of the MAPEG family of integral membrane proteins. Curr. Opin. Struct. Biol. \n                           18, 442\u2013449, doi:10.1016\/j.sbi.2008.04.005 (2008).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"9795_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1432-1033.1996.0606w.x","volume":"238","author":"BK Lam","year":"1996","unstructured":"Lam, B. K. et al. Molecular cloning, expression and characterization of mouse leukotriene C4 synthase. Eur. J. Biochem. \n                           238, 606\u2013612 (1996).","journal-title":"Eur. J. Biochem."},{"key":"9795_CR36","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.4049\/jimmunol.170.9.4738","volume":"170","author":"D Claveau","year":"2003","unstructured":"Claveau, D. et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. \n                           170, 4738\u20134744 (2003).","journal-title":"J. Immunol."},{"key":"9795_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1096\/fj.15-278010","volume":"30","author":"J Gerstmeier","year":"2016","unstructured":"Gerstmeier, J. et al. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase\/5-lipoxygenase-activating protein complex in blood leukocytes. FASEB J. \n                           30, 276\u2013285, doi:10.1096\/fj.15-278010 (2016).","journal-title":"FASEB J."},{"key":"9795_CR38","doi-asserted-by":"publisher","first-page":"20434","DOI":"10.1073\/pnas.0808211106","volume":"105","author":"AK Mandal","year":"2008","unstructured":"Mandal, A. K. et al. The nuclear membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. USA \n                           105, 20434\u201320439, doi:10.1073\/pnas.0808211106 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9795_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2014.05.011","volume":"87","author":"A Rossi","year":"2014","unstructured":"Rossi, A. et al. In vivo sex differences in leukotriene biosynthesis in zymosan-induced peritonitis. Pharmacol Res \n                           87, 1\u20137, doi:10.1016\/j.phrs.2014.05.011 (2014).","journal-title":"Pharmacol Res"},{"key":"9795_CR40","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.bmcl.2015.04.090","volume":"25","author":"D Pettersen","year":"2015","unstructured":"Pettersen, D., Davidsson, O. & Whatling, C. Recent advances for FLAP inhibitors. Bioorg. Med. Chem. Lett. \n                           25, 2607\u20132612, doi:10.1016\/j.bmcl.2015.04.090 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"9795_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/343278a0","volume":"343","author":"DK Miller","year":"1990","unstructured":"Miller, D. K. et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature \n                           343, 278\u2013281, doi:10.1038\/343278a0 (1990).","journal-title":"Nature"},{"key":"9795_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1084\/jem.185.6.1065","volume":"185","author":"RS Byrum","year":"1997","unstructured":"Byrum, R. S., Goulet, J. L., Griffiths, R. J. & Koller, B. H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. \n                           185, 1065\u20131075 (1997).","journal-title":"J. Exp. Med."},{"key":"9795_CR43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.1144346","volume":"317","author":"AD Ferguson","year":"2007","unstructured":"Ferguson, A. D. et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science \n                           317, 510\u2013512, doi:10.1126\/science.1144346 (2007).","journal-title":"Science"},{"key":"9795_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1432-1033.1993.tb18012.x","volume":"215","author":"M Abramovitz","year":"1993","unstructured":"Abramovitz, M. et al. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem. \n                           215, 105\u2013111 (1993).","journal-title":"Eur. J. Biochem."},{"key":"9795_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/sj.bjp.0707416","volume":"152","author":"L Fischer","year":"2007","unstructured":"Fischer, L. et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br. J. Pharmacol. \n                           152, 471\u2013480, doi:10.1038\/sj.bjp.0707416 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"9795_CR46","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/jm201468j","volume":"55","author":"HC Shen","year":"2012","unstructured":"Shen, H. C. & Hammock, B. D. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J. Med. Chem. \n                           55, 1789\u20131808, doi:10.1021\/jm201468j (2012).","journal-title":"J. Med. Chem."},{"key":"9795_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1152\/physrev.00021.2011","volume":"92","author":"JD Imig","year":"2012","unstructured":"Imig, J. D. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. \n                           92, 101\u2013130, doi:10.1152\/physrev.00021.2011 (2012).","journal-title":"Physiol. Rev."},{"key":"9795_CR48","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1073\/pnas.0503279102","volume":"102","author":"KR Schmelzer","year":"2005","unstructured":"Schmelzer, K. R. et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U S A \n                           102, 9772\u20139777, doi:10.1073\/pnas.0503279102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"9795_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/cvr\/cvr267","volume":"93","author":"HH Hou","year":"2012","unstructured":"Hou, H. H. et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc. Res. \n                           93, 120\u2013129, doi:10.1093\/cvr\/cvr267 (2012).","journal-title":"Cardiovasc. Res."},{"key":"9795_CR50","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.1073\/pnas.91.16.7663","volume":"91","author":"BK Lam","year":"1994","unstructured":"Lam, B. K., Penrose, J. F., Freeman, G. J. & Austen, K. F. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. USA \n                           91, 7663\u20137667 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9795_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature \n                           510, 92\u2013101, doi:10.1038\/nature13479 (2014).","journal-title":"Nature"},{"key":"9795_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature12175","volume":"498","author":"T Lammermann","year":"2013","unstructured":"Lammermann, T. et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature \n                           498, 371\u2013375, doi:10.1038\/nature12175 (2013).","journal-title":"Nature"},{"key":"9795_CR53","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJMra071371","volume":"357","author":"M Peters-Golden","year":"2007","unstructured":"Peters-Golden, M. & Henderson, W. R. Jr. Leukotrienes. N. Engl. J. Med. \n                           357, 1841\u20131854, doi:10.1056\/NEJMra071371 (2007).","journal-title":"N. Engl. J. Med."},{"key":"9795_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11936-006-0011-0","volume":"8","author":"H Hakonarson","year":"2006","unstructured":"Hakonarson, H. Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options. Curr. Treat Options Cardiovasc. Med. \n                           8, 183\u2013192 (2006).","journal-title":"Curr. Treat Options Cardiovasc. Med."},{"key":"9795_CR55","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2174\/0929867311320130013","volume":"20","author":"SH Hwang","year":"2013","unstructured":"Hwang, S. H., Wecksler, A. T., Wagner, K. & Hammock, B. D. Rationally designed multitarget agents against inflammation and pain. Curr. Med. Chem. \n                           20, 1783\u20131799 (2013).","journal-title":"Curr. Med. Chem."},{"key":"9795_CR56","first-page":"77","volume":"97","author":"A Boyum","year":"1968","unstructured":"Boyum, A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. Suppl \n                           97, 77\u201389 (1968).","journal-title":"J. Clin. Lab. Invest. Suppl"},{"key":"9795_CR57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1096\/fj.03-0205com","volume":"17","author":"L Fischer","year":"2003","unstructured":"Fischer, L., Szellas, D., Radmark, O., Steinhilber, D. & Werz, O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. \n                           17, 949\u2013951, doi:10.1096\/fj.02-0815fje (2003).","journal-title":"FASEB J."},{"key":"9795_CR58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0378-4347(00)82742-5","volume":"493","author":"D Steinhilber","year":"1989","unstructured":"Steinhilber, D., Herrmann, T. & Roth, H. J. Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a Radial-Pak cartridge after extraction with an octadecyl reversed-phase column. J. Chromatogr. \n                           493, 361\u2013366 (1989).","journal-title":"J. Chromatogr."},{"key":"9795_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0003-2697(88)90256-4","volume":"169","author":"RN Wixtrom","year":"1988","unstructured":"Wixtrom, R. N., Silva, M. H. & Hammock, B. D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. Anal. Biochem. \n                           169, 71\u201380 (1988).","journal-title":"Anal. Biochem."},{"key":"9795_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/acs.jcim.5b00592","volume":"56","author":"B Waltenberger","year":"2016","unstructured":"Waltenberger, B. et al. Discovery of Potent Soluble Epoxide Hydrolase (sEH) Inhibitors by Pharmacophore-Based Virtual Screening. J. Chem. Inf. Model \n                           56, 747\u2013762, doi:10.1021\/acs.jcim.5b00592 (2016).","journal-title":"J. Chem. Inf. Model"},{"key":"9795_CR61","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/1087057116637609","volume":"21","author":"FM Klingler","year":"2016","unstructured":"Klingler, F. M., Wolf, M., Wittmann, S., Gribbon, P. & Proschak, E. Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase. J. Biomol. Screen. \n                           21, 689\u2013694, doi:10.1177\/1087057116637609 (2016).","journal-title":"J. Biomol. Screen."},{"key":"9795_CR62","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1124\/jpet.108.139444","volume":"326","author":"A Koeberle","year":"2008","unstructured":"Koeberle, A. et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther. \n                           326, 975\u2013982, doi:10.1124\/jpet.108.139444 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9795_CR63","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.bbalip.2016.07.011","volume":"1861","author":"S Liening","year":"2016","unstructured":"Liening, S. et al. Development of smart cell-free and cell-based assay systems for investigation of leukotriene C4 synthase activity and evaluation of inhibitors. Biochim. Biophys. Acta. \n                           1861, 1605\u20131613, doi:10.1016\/j.bbalip.2016.07.011 (2016).","journal-title":"Biochim. Biophys. Acta."},{"key":"9795_CR64","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0006-2952(02)01387-4","volume":"64","author":"D Albert","year":"2002","unstructured":"Albert, D. et al. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol. \n                           64, 1767\u20131775 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"9795_CR65","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O Soderberg","year":"2006","unstructured":"Soderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods \n                           3, 995\u20131000, doi:10.1038\/nmeth947 (2006).","journal-title":"Nat. Methods"},{"key":"9795_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. \n                           8, e1000412, doi:10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS Biol."},{"key":"9795_CR67","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.mce.2008.01.026","volume":"286","author":"I Matias","year":"2008","unstructured":"Matias, I. et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol. Cell. Endocrinol. \n                           286, S66\u201378, doi:10.1016\/j.mce.2008.01.026 (2008).","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09795-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:21:43Z","timestamp":1671787303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09795-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9795"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09795-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9398"}}